Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics Spectra BioPhotonics EuroPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook

Novara Therapeutics Will Deliver ‘Bone-Targeting’ Contrast Agent for Diagnostic Imaging

Facebook Twitter LinkedIn Email Comments
LONDON, Sept. 24, 2020 — Orthopaedic Research UK and Embryo Ventures have formed Novara Therapeutics. The joint venture company will commercialize a “bone-targeting” contrast agent that improves the quality of normative diagnostic imaging, which is particularly applicable to the diagnosis and treatment of osteoporosis.

Contrast agents, often used to improve medical imaging quality, commonly lack tissue specificity and the ability to provide therapeutic action. The Novara agent aims to specifically support the diagnostic and interventional procedures of osteoporotic fractures.

Photonics.com
Sep 2020
orthopedicorthopedicsbonemedical imagingtissueBiophotonicsosteoporosiscontrast agentcontrast agentsimagingmedicalmedicinebiotech

Comments
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2020 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, [email protected]

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.